Search results for "Subfamily B"

showing 5 items of 125 documents

Transporter (TAP)- and proteasome-independent presentation of a melanoma-associated tyrosinase epitope.

2000

The melanosomal protein tyrosinase is considered as a target of specific immunotherapy against melanoma. Two tyrosinase-derived peptides are presented in association with HLA-A2.1 [Wolfel et al., Eur. J. Immunol., 24, 759-764 (1994)]. Peptide 1-9 (MLLAVLYCL) is generated from the putative signal sequence. The internal peptide 369-377 is posttranslationally converted at residue 371, and its presentation is dependent on functional TAP transporters and proteasomes [Mosse et al., J. exp. Med.187, 37-48 (1998)]. Herein, we report on the processing and transport requirements for the signal sequence-derived peptide 1-9 that were studied in parallel to those for peptide 369-377. After infection of …

Signal peptideCancer ResearchProteasome Endopeptidase ComplexLactacystinAntigen presentationTyrosinase PeptidePeptideBiologyProtein Sorting SignalsEpitopechemistry.chemical_compoundEpitopesMultienzyme ComplexesHLA-A2 AntigenTumor Cells CulturedHumansATP Binding Cassette Transporter Subfamily B Member 2Melanomachemistry.chemical_classificationAntigen PresentationMonophenol MonooxygenaseCell biologyCTL*Cysteine EndopeptidasesOncologychemistryProteasomeBiochemistryATP-Binding Cassette TransportersT-Lymphocytes CytotoxicInternational journal of cancer
researchProduct

Identification of a Terphenyl Derivative that Blocks the Cell Cycle in the G0−G1 Phase and Induces Differentiation in Leukemia Cells

2006

To further explore the SAR of resveratrol-related trans-stilbene derivatives, here we describe the synthesis of (a) a series of 3,5-dimethoxy analogues in which a variety of substituents were introduced at positions 2', 3', 4', and 5' of the stilbene scaffold and (b) a second group of derivatives (2-phenylnaphthalenes and terphenyls) that incorporate a phenyl ring as a bioisosteric replacement of the stilbene alkenyl bridge. We thoroughly characterized all of the new compounds with respect to their apoptosis-inducing activity and their effects on the cell cycle. One of the new derivatives, 13g, behaved differently from the others, as it was able to block the cell cycle in the G(0)-G(1) phas…

StereochemistryCellular differentiationFusion Proteins bcr-ablAntineoplastic AgentsApoptosis.ResveratrolResting Phase Cell CycleChemical synthesisStructure-Activity Relationshipchemistry.chemical_compoundLeukemia Promyelocytic AcuteCell Line TumorTerphenyl CompoundsTerphenylStilbenesDrug DiscoveryHumansStructure–activity relationshipATP Binding Cassette Transporter Subfamily B Member 1G1 PhaseCell DifferentiationCell cycleIn vitrochemistryDrug Resistance NeoplasmResveratrolCell cultureMolecular MedicineDrug Screening Assays AntitumorJournal of Medicinal Chemistry
researchProduct

Cytotoxicity and inhibition of P-glycoprotein by selected medicinal plants from Thailand.

2014

Abstract Ethnopharmacological relevance Thai medicine has a long tradition of tonifying medicinal plants. In the present investigation, we studied the flower extracts of Jasminum sambac, Mammea siamensis, Mesua ferrea, Michelia alba, Mimusops elengi, and Nelumbo nucifera and speculated that these plants might influence metabolism and substance flow in the body. Materials and methods Isolation of porcine brain capillary endothelial cells (PBCECs) as well as multidrug-resistance CEM/ADR5000 leukemia cells, MDA-M;B-231 breast cancer, U-251 brain tumor, and HCT-116 colon cancer cells were used. The calcein-acetoxymethylester (AM) assay was used to measure inhibition of P-glycoprotein transport.…

SwineMesua ferreaMimusops elengiFlowersPharmacologyBlood–brain barrierchemistry.chemical_compoundCell Line TumorNeoplasmsDrug DiscoverymedicineAnimalsHumansATP Binding Cassette Transporter Subfamily B Member 1CytotoxicityP-glycoproteinPharmacologyMedicine East Asian TraditionalPlants MedicinalbiologyTraditional medicinePlant ExtractsMammeaBrainEndothelial Cellsmedicine.diseasebiology.organism_classificationThailandAntineoplastic Agents PhytogenicDrug Resistance MultipleLeukemiamedicine.anatomical_structurechemistryBlood-Brain BarrierDrug Resistance Neoplasmbiology.proteinEndothelium VascularGrowth inhibitionJournal of ethnopharmacology
researchProduct

In vitro evaluation of glycol chitosan based formulations as oral delivery systems for efflux pump inhibition.

2017

Recently, we have reported that glycol chitosan (GCS) was able to reverse the P- glycoprotein (P-gp) efflux pump. The objective of the present study was to evaluate the potential of two GCS-based dosage forms (aqueous solution or nanoparticle suspension) for oral administration of the P-gp substrate Rho-123. A further aim of the present study was to assess the effect of the glycol chitosan-4-thiobutylamidine thiomer (GCS-TBA) on P-gp activity considering that the corresponding thiomer of chitosan series is a well-known P-gp inhibitor. Pre-treatment of Caco-2 cell monolayer with a GCS solution or GCS-based nanoparticles increased the absorptive transport of Rho-123 across the monolayer of 1.…

endocrine systemATP Binding Cassette Transporter Subfamily BPolymers and Plastics02 engineering and technologyPharmacologyDosage formChitosan03 medical and health scienceschemistry.chemical_compoundGlycols0302 clinical medicineDrug Delivery SystemsOral administrationhealth services administrationpolycyclic compoundsMaterials ChemistryHumansGlycol chitosan-based formulations P-gp inhibition properties Rhodamine 123 Glycol chitosan-4-thiobutylamidine thiomer Caco-2 cells Oral bioavailabilityChitosanChemistryThiomerOrganic ChemistryGlycol chitosan-based formulations P-gp inhibition properties Rhodamine 123 Glycol chitosan-4-thiobutylamidine thiomer Caco-2 cells Oral bioavailability021001 nanoscience & nanotechnologyBioavailabilityCaco-2Settore CHIM/09 - Farmaceutico Tecnologico Applicativo030220 oncology & carcinogenesisNanoparticlessense organsEffluxCaco-2 Cells0210 nano-technologyhormones hormone substitutes and hormone antagonistsConjugateCarbohydrate polymers
researchProduct

Burden of illness of progressive familial intrahepatic cholestasis in the US, UK, France, and Germany: study rationale and protocol of the PICTURE st…

2021

Background: Progressive familial intrahepatic cholestasis (PFIC) is an ultra-rare disease with a considerable burden on pediatric patients and their caregivers, impacting quality of life (QoL). The mortality rates highlight a significant need for efficacious treatments. Real-world data on associated costs and QoL are needed to gauge the potential impact of new pharmacological treatments. Methods: Clinical and socio-economic burden of PFIC on patients/caregivers, health systems, and society will be assessed. Patient/caregiver- and physician-level retrospective cross-sectional data will be collected from the US, UK, France, and Germany, for PFIC types 1, 2, 3. A representative sample of physi…

medicine.medical_specialtyATP Binding Cassette Transporter Subfamily BCaregiver BurdenDiseaseCholestasis Intrahepatic03 medical and health sciences0302 clinical medicineQuality of lifeCost of IllnessSurveys and QuestionnairesMedicineHumansPharmacology (medical)030212 general & internal medicineCase report formDisease burdenHealth policyRetrospective Studiesbusiness.industry030503 health policy & servicesHealth PolicyMortality rateProgressive familial intrahepatic cholestasisHealth technologyGeneral Medicinemedicine.diseaseCross-Sectional StudiesSocioeconomic FactorsFamily medicineQuality of Life0305 other medical sciencebusinessDelivery of Health Care
researchProduct